On May 19, 2020, Innovation Pharma announced that its anti-SARS-CoV-2 (COVID-19) drug candidate, Brilacidin, in an in vitro experiment using VERO cells, reduced the viral titer (load) of SARS-CoV-2 by 75 percent after only 1 hour of preincubation prior to infection at a concentration of 10ﾵM as compared to vehicle control.

Additional time-dependent and concentration-dependent experiments are underway to further delineate Brilacidinﾒs virucidal properties against SARS-CoV-2.